These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31322224)

  • 1. Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin.
    Deng M; Sun J; Xie S; Zhen H; Wang Y; Zhong A; Zhang H; Lu R; Guo L
    Mol Med Rep; 2019 Sep; 20(3):2258-2266. PubMed ID: 31322224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.
    Mao D; Che J; Han S; Zhao H; Zhu Y; Zhu H
    Mol Med Rep; 2015 Nov; 12(5):6635-41. PubMed ID: 26299671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Zhong A; Zhang H; Xie S; Deng M; Zheng H; Wang Y; Chen M; Lu R; Guo L
    Oncol Rep; 2018 Apr; 39(4):1747-1756. PubMed ID: 29393493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pixantrone as a novel MCM2 inhibitor for ovarian cancer treatment.
    Chen Q; Sun Y; Li H; Liu S; Zhang H; Cheng Z; Wang Y
    Eur J Pharmacol; 2024 Sep; 979():176835. PubMed ID: 39032764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
    Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
    Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.
    Wang L; Yan W; Li X; Liu Z; Tian T; Chen T; Zou L; Cui Z
    J Ovarian Res; 2019 Nov; 12(1):113. PubMed ID: 31739800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
    Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
    Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APE1 overexpression promotes the progression of ovarian cancer and serves as a potential therapeutic target.
    Wen X; Lu R; Xie S; Zheng H; Wang H; Wang Y; Sun J; Gao X; Guo L
    Cancer Biomark; 2016 Sep; 17(3):313-322. PubMed ID: 27802207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
    Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
    PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas.
    Zhang X; Teng Y; Yang F; Wang M; Hong X; Ye LG; Gao YN; Chen GY
    Oncol Rep; 2015 May; 33(5):2599-605. PubMed ID: 25738322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway.
    Zhou H; Zhao H; Liu H; Xu X; Dong X; Zhao E
    J BUON; 2018; 23(6):1732-1738. PubMed ID: 30610801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Long Noncoding RNA E2F-Mediated Cell Proliferation Enhancing Long Noncoding RNA Is Involved in the Development of Chemoresistance of Cancer Cells to Carboplatin in Ovarian Endometrioid Adenocarcinoma.
    Zhao L; Yang J; Liu X; Fu X; Ding Y; Wang C
    Cancer Biother Radiopharm; 2019 Nov; 34(9):566-571. PubMed ID: 31621389
    [No Abstract]   [Full Text] [Related]  

  • 16. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
    Wang H; Zhu L; Gao J; Hu Z; Lin B
    Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAU regulates carboplatin resistance in ovarian cancer.
    Moss EL; Mourtada-Maarabouni M; Pickard MR; Redman CW; Williams GT
    Genes Chromosomes Cancer; 2010 Jan; 49(1):70-7. PubMed ID: 19830698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
    Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
    Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.